An update on adrenocortical cell lines of human origin

Sandra Sigala¹, Elisa Rossini¹, Andrea Abate¹, Mariangela Tamburello¹, Stefan R Bornstein^{2

3

4

5

6

7}, Constanze Hantel^{8

9}

Affiliations

¹ Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, 25124, Brescia, Italy.
² Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), 8091, Zürich, Switzerland.
³ Medizinische Klinik und Poliklinik III, University Hospital Carl Gustav Carus Dresden, 01307, Dresden, Germany.
⁴ Diabetes and Nutritional Sciences, King's College London, London, WC2R 2LS, UK.
⁵ Center for Regenerative Therapies, Technische Universität Dresden, 01307, Dresden, Germany.
⁶ Paul-Langerhans-Institute Dresden, Helmholtz Center Munich, University Hospital Carl Gustav Carus, Faculty of Medicine, Technische Universität Dresden, 01307, Dresden, Germany.
⁷ Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 636921, Singapore.
⁸ Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), 8091, Zürich, Switzerland. Constanze.Hantel@usz.ch.
⁹ Medizinische Klinik und Poliklinik III, University Hospital Carl Gustav Carus Dresden, 01307, Dresden, Germany. Constanze.Hantel@usz.ch.

PMID: 35764904
PMCID: PMC9385758
DOI: 10.1007/s12020-022-03112-w

Review

An update on adrenocortical cell lines of human origin

Sandra Sigala et al. Endocrine. 2022 Sep.

. 2022 Sep;77(3):432-437.

doi: 10.1007/s12020-022-03112-w. Epub 2022 Jun 28.

Authors

Sandra Sigala¹, Elisa Rossini¹, Andrea Abate¹, Mariangela Tamburello¹, Stefan R Bornstein^{2

3

4

5

6

7}, Constanze Hantel^{8

9}

Affiliations

¹ Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, 25124, Brescia, Italy.
² Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), 8091, Zürich, Switzerland.
³ Medizinische Klinik und Poliklinik III, University Hospital Carl Gustav Carus Dresden, 01307, Dresden, Germany.
⁴ Diabetes and Nutritional Sciences, King's College London, London, WC2R 2LS, UK.
⁵ Center for Regenerative Therapies, Technische Universität Dresden, 01307, Dresden, Germany.
⁶ Paul-Langerhans-Institute Dresden, Helmholtz Center Munich, University Hospital Carl Gustav Carus, Faculty of Medicine, Technische Universität Dresden, 01307, Dresden, Germany.
⁷ Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 636921, Singapore.
⁸ Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), 8091, Zürich, Switzerland. Constanze.Hantel@usz.ch.
⁹ Medizinische Klinik und Poliklinik III, University Hospital Carl Gustav Carus Dresden, 01307, Dresden, Germany. Constanze.Hantel@usz.ch.

PMID: 35764904
PMCID: PMC9385758
DOI: 10.1007/s12020-022-03112-w

Abstract

Adrenocortical carcinoma (ACC) is a rare, heterogenous and highly malignant disease. Management of ACC is dependent on disease stage with complete surgical resection as the only potentially curative option. However, advanced, un-resectable, metastatic stages and also recurrences often require systemic treatments, which are unfortunately nowadays still unsatisfactory. The scarcity of preclinical models reflecting patient heterogeneities and furthermore drug-resistant phenotypes, has hampered the progress and development of new therapies in recent years. In this review, we provide an overview on the classical models and substantial progress which has been made over the last years in context of this aggressive disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

**Fig. 1**
Overview in the currently available human adrenocortical cell lines. Modified from [12]

See this image and copyright information in PMC

Comment in

Eighth International Adrenal Cancer Symposium Brescia, Italy, September 30 to October 1-2, 2021.
Berruti A, Terzolo M, Filetti S. Berruti A, et al. Endocrine. 2022 Sep;77(3):409-410. doi: 10.1007/s12020-022-03147-z. Endocrine. 2022. PMID: 35867326 Free PMC article. No abstract available.

References

1. Kiesewetter B, et al. Management of adrenocortical carcinoma: are we making progress? Ther. Adv. Med. Oncol. 2021;13:17588359211038409. - PMC - PubMed
1. Fassnacht M, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2020;31(11):1476–1490. - PubMed
1. Gazdar AF, et al. Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res. 1990;50(17):5488–5496. - PubMed
1. Dierks A, et al. Identification of adrenal genes regulated in a potassium-dependent manner. J. Mol. Endocrinol. 2010;45(4):193–206. - PubMed
1. Ahmed KEM, et al. LC-MS/MS based profiling and dynamic modelling of the steroidogenesis pathway in adrenocarcinoma H295R cells. Toxicol. Vitr. 2018;52:332–341. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

An update on adrenocortical cell lines of human origin

Affiliations

An update on adrenocortical cell lines of human origin

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Comment in

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources